LXEO
Lexeo Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LXEO
Lexeo Therapeutics, Inc.
A clinical-stage genetic medicine company treating cardiovascular disease and Alzheimer's disease
345 Park Avenue South, Floor 6, New York, New York 10010
--
Lexeo Therapeutics, Inc., formed on February 17, 2017, is a limited liability company organized under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company converted the LLC to Lexeo Therapeutics, Inc., a Delaware-based company on November 20, 2020. The company is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying groundbreaking science to fundamentally change the way diseases are treated. The company's most advanced cardiovascular product candidate, LX 2006, is currently in an ongoing Phase 1/2 clinical trial for the treatment of patients with Friedreich's ataxia (FA) cardiomyopathy. The company's second advanced cardiovascular product candidate, LX2020, for the treatment of arrhythmogenic cardiomyopathy caused by mutations in the PKP 2 gene, referred to as PKP 2-ACM, received IND approval from the U.S. Food and Drug Administration (FDA) in July 2023.
Company Financials
EPS
LXEO has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.44, beating expectations. The chart below visualizes how LXEO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
